Adicet Bio, Inc.

Equities

ACET

US0070021086

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:13:32 2024-05-23 EDT			5-day change	1st Jan Change
1.595 ^USD	-2.15%		+1.91%	-15.34%

05-14	Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	CI

Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 08, 2022 at 04:16 pm

Adicet Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 22 million compared to USD 14.01 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.44 a year ago.
For the nine months, sales was USD 24.99 million compared to USD 4.26 million a year ago. Net loss was USD 39.92 million compared to USD 46.19 million a year ago. Basic loss per share from continuing operations was USD 0.98 compared to USD 1.54 a year ago.

Latest news about Adicet Bio, Inc.

Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	04-22	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
JonesTrading Upgrades Adicet Bio to Buy From Hold, Price Target is $6	02-14	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	01-23	MT
Adicet Bio Prices $85.2 Million Share Offering	01-23	MT
Adicet Bio Launches Securities Offering; Shares Rise After-Hours	01-22	MT
Transcript : Adicet Bio, Inc. - Special Call	01-04
Adicet Bio, Inc.(NasdaqGM:ACET) dropped from NASDAQ Biotechnology Index	12-15	CI
Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting	12-10	CI
Adicet Bio, Inc. Announces Board Changes	11-13	CI
Wedbush Lowers Adicet Bio's PT to $5 From $17, Adjusts Model to Reflect More Focused Strategy; Retains Outperform Rating	11-09	MT
Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Adjusts Adicet Bio Price Target to $26 From $38, Maintains Buy Rating	23-08-11	MT
Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors	23-07-11	CI
Insider Buy: Adicet Bio	23-06-29	MT
North American Morning Briefing : Chip Stocks Take -2-	23-06-28	DJ
Guggenheim Downgrades Adicet Bio to Neutral From Buy	23-06-27	MT
JonesTrading Downgrades Adicet Bio to Hold From Buy	23-06-27	MT
JMP Securities Downgrades Adicet Bio to Market Perform From Market Outperform	23-06-27	MT
Wedbush Cuts Adicet Bio's Price Target to $17 From $30 to be Conservative as Focus Remains on Post CAR-T Setting; Keeps Outperform Rating	23-06-27	MT

Chart Adicet Bio, Inc.

Duration

Period

More charts

Company Profile

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.63 USD

Average target price

9 USD

Spread / Average Target

+452.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADICET BIO, INC.	-15.34%	134M
MODERNA, INC.	+63.31%	62.59B
IQVIA HOLDINGS INC.	-0.98%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.17%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.45%	19.09B
BIO-TECHNE CORPORATION	+5.17%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.09%	12.26B
MEDPACE HOLDINGS, INC.	+28.39%	12.05B

Other Biotechnology & Medical Research